PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
118.91%
Cash & equivalents yoy growth 1.25-1.5x RVPH's 95.93%. Bruce Berkowitz would examine if higher cash accumulation is strategic or just idle.
No Data
No Data available this quarter, please select a different quarter.
118.91%
Cash + STI yoy 1.25-1.5x RVPH's 95.93%. Bruce Berkowitz would check if the firm is preparing for expansions or simply hoarding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
104.59%
1.25-1.5x RVPH's 72.84%. Bruce Berkowitz checks if strong current asset growth is used effectively.
15.06%
Higher PP&E (Net) Growth compared to RVPH's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.06%
Higher Other Non-Current Assets Growth compared to RVPH's zero value, indicating worse performance.
15.06%
Higher Total Non-Current Assets Growth compared to RVPH's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
104.51%
≥ 1.5x RVPH's 64.40%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
55.57%
Above 1.5x RVPH's 5.25%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
719.98%
Exceeding 1.5x RVPH's 8.21%. Michael Burry suspects ballooning short-term obligations vs. competitor.
14812.60%
Above 1.5x RVPH's 4.94%. Michael Burry sees a red flag for liquidity risk vs. competitor.
-100.00%
Higher Long-Term Debt Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x RVPH's -40.00%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
4364.90%
Above 1.5x RVPH's 4.83%. Michael Burry sees a potential leverage warning sign.
91.77%
Above 1.5x RVPH's 45.49%. Michael Burry suspects heavy new equity expansion or dilution.
-19849.13%
≥ 1.5x RVPH's -3.55%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1201.65%
≥ 1.5x RVPH's 89.71%. David Dodd sees stronger capital base growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
92.16%
Less than half of RVPH's -49.51%. David Dodd sees less overall debt expansion vs. competitor.
-119.69%
1.1-1.25x RVPH's -102.37%. Bill Ackman questions if net debt is increasing faster than competitor.